

## REMARKS

This is in response to the Office Action mailed on September 24, 2007. Claims 19-29 are currently pending and are at issue.

According to the Examiner's suggestion, Applicants have amended the specification to introduce Section Headings and to correct other informalities.

Claim 24 has been further amended to recite "immunogenic" fragment of the G protein. Support can be found, for example, at page 5, lines 12-16.


### §112, Second Paragraph

The Office Action rejected claims 19-29 under 35 U.S.C. §112, second paragraph as allegedly being indefinite. Applicants have amended claims 19-22 and 24-29 and have canceled claim 23. Applicants believe that the amendments address and overcome the rejection.

### Conclusion

Applicants respectfully submit that all rejections have been overcome by amendments and/or arguments. Favorable consideration and allowance of claims is respectfully requested. If the Examiner has any questions or concerns, she is welcome to telephone the undersigned attorney.

Respectfully submitted,

  
Mark V. Polyakov, Reg. No. 54,377


Wood, Phillips, Katz, Clark & Mortimer  
500 West Madison Street, Suite 3800  
Chicago, Illinois 60661-4592  
Telephone: (312) 876-1800  
Facsimile: (312) 876-2020  
Date: December 26, 2007



Response to OA dated 09/24/2007  
10/815,320  
PIE01514P00182US

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage at First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on **December 26, 2007.**

  
Alicia Diaz